[HTML][HTML] Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management

A Scarabosio, PL Surico, RB Singh… - Journal of Personalized …, 2024 - mdpi.com
Thyroid Eye Disease (TED) is a debilitating autoimmune condition often associated with
thyroid dysfunction, leading to significant ocular and orbital morbidity. This review explores …

Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review

X Li, S Li, W Fan, AC Rokohl, S Ju, X Ju, Y Guo… - International …, 2023 - Springer
Graves ophthalmopathy (GO), which occurs in autoimmune thyroid disease, can reduce
patients' quality of life due to its impact on visual function, physical appearance, and …

[HTML][HTML] Thyroid eye disease

J Szelog, H Swanson, MC Sniegowski… - Missouri Medicine, 2022 - ncbi.nlm.nih.gov
Thyroid eye disease, although rare, is the most common inflammatory orbital disorder and is
associated with autoimmune thyroid dysfunction. It is a progressive disorder with symptoms …

Thyroid-associated orbitopathy: management and treatment

L Hennein, SL Robbins - Journal of Binocular Vision and Ocular …, 2022 - Taylor & Francis
Thyroid-associated orbitopathy (TAO) is a leading cause of orbital and strabismus symptoms
in adults. Over the last decade, new treatments have greatly changed available options to …

Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease

V Gupta, CL Hammond, E Roztocil, MO Gonzalez… - Survey of …, 2022 - Elsevier
Thyroid eye disease (TED) is an autoimmune disorder that manifests in the orbit. In TED, the
connective tissue behind the eye becomes inflamed and remodels with increased fat …

Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?

NF Xavier, DT Lucena, AAV Cruz - Ophthalmic Plastic & …, 2023 - journals.lww.com
Purpose: To summarize the development, nomenclature, and rationale of the reported use of
monoclonal antibodies (Mabs) in Graves Orbitopathy (GO) and to undertake a systematic …

[HTML][HTML] Compounded medications for ocular surface disease

EH Lee, GD Novack - The Ocular Surface, 2021 - ncbi.nlm.nih.gov
Most of us have found ourselves spending more time at home during the COVID-19
pandemic. One of us (EHL) decided to try his hand at baking pies from scratch. Four weeks …

[HTML][HTML] Oculoplastic publication trends in general ophthalmology journals

JP Dray, N Khatib, E Souied, P Saeed… - International Journal …, 2022 - ncbi.nlm.nih.gov
AIM To examine the publication trend of oculoplastic articles throughout the last decade in
general ophthalmology journals. METHODS A review of all abstracts published between …

A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface

S Ugradar, AL Kossler, R Douglas… - Journal of Neuro …, 2022 - journals.lww.com
Background: Teprotumumab, a monoclonal antibody that blocks the insulin-like growth
factor-1 receptor, has recently been approved by the US Food and Drug Administration …

Eyes on new product development

GD Novack - Journal of Ocular Pharmacology and Therapeutics, 2019 - liebertpub.com
In this period, new drug delivery programs were an-nounced, including quantum dots and
erodible intraocular implants. Also reported were clinical results on systems using contact …